WilliamJohnsonIrvinJr.MD

Oncology • Midlothian, VA

Assistant Professor, Medicine, University of North Carolina-Chapel Hill School of Medicine

Join to view full profile

Dr. Irvin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Irvin's full profile

Already have an account?

Office
14051 St Francis Blvd
Suite 2210
Midlothian, VA 23114
Phone+1 804-893-8717

Fax+1 804-594-3131
Is this information wrong?

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2006 - 2009
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2003 - 2006
Virginia Commonwealth University School of MedicineClass of 2003

Certifications & Licensure

NC State Medical License 2006 - 2024
VA State Medical License 2003 - 2024
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen Start of enrollment: 2008 Jun 18
Completed
Phase 2
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
Completed
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Benjamin J Bulen, Nickolay A Khazanov, Daniel H Hovelson, Laura E Lamb, Marc Matrana, Mark E Burkard, Eddy Shih-Hsin Yang, William J Edenfield, Elizabeth Claire Dees, ...> ;Cancer Research Communications. 2023 Jul 1
5 citations
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
Ciara C. O’Sullivan, Karla V. Ballman, Linda M. McCall, Anuhya Kommalapati, Tyler Zemla, Anna Weiss, Melissa Mitchell, Victoria S. Blinder, Nadine Tung, William J. Irv...> ;Future Oncology. 2021 Oct 12
13 citations
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.
Scott A. Tomlins, Daniel H. Hovelson, Jennifer Marie Suga, Daniel M. Anderson, Han A. Koh, Elizabeth Claire Dees, Brendan McNulty, Mark E. Burkard, Michael Guarino, Ja...> ;JCO Precision Oncology. 2021 Aug 19
23 citations
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP s...
Natasha B. Leighl, Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, James L. Wade, William J. Irvin, Sreekanth Reddy, Jeffrey Cra...> ;Journal for Immunotherapy of Cancer. 2021 Aug 1
24 citations
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or H...
Beverly Moy, R. Bryan Rumble, Steven E. Come, Nancy E. Davidson, Angelo Di Leo, Julie R. Gralow, Gabriel N. Hortobagyi, Douglas Yee, Ian E. Smith, Mariana Chavez-MacGr...> ;Journal of Clinical Oncology. 2021 Jul 29
12 citations
Nab-paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy
Jared Weiss, Nathan A. Pennell, Allison M. Deal, Daniel Morgensztern, Daniel S. Bradford, Jeffrey Crane, Howard Jack West, Carrie B. Lee, Chad V. Pecot, James P. Steve...> ;Cancer. 2020 Mar 1
12 citations
Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment
Lauren A Marcath, Allison M. Deal, Emily Van Wieren, William Danko, Christine M. Walko, Joseph G. Ibrahim, Karen E. Weck, David R. Jones, Zeruesenay Desta, Howard L. M...> ;Pharmacogenetics and Genomics. 2017 Nov 1
37 citations
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity
Daniel L. Hertz, Allison M. Deal, Joseph G. Ibrahim, Christine M. Walko, Karen E. Weck, Steven M. Anderson, Gustav Magrinat, Oludamilola Olajide, Susan E. Moore, Rache...> ;The Oncologist. 2016 Jul 1
39 citations
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles
Daniel L. Hertz, Anna C. Snavely, Howard L. McLeod, Christine M. Walko, Joseph G. Ibrahim, Steven M. Anderson, Karen E. Weck, Gustav Magrinat, Oludamilola Olajide, Sus...> ;British Journal of Clinical Pharmacology. 2015 Nov 1
47 citations
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-...
Andres Forero-Torres, Katherine E. Varley, Vandana G. Abramson, Yufeng Li, Christos Vaklavas, Nan Lin, Minetta C. Liu, Hope S. Rugo, Rita Nanda, Anna Maria Storniolo, ...> ;Clinical Cancer Research. 2015 Jun 15
67 citations
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
Costanza Paoletti, Yufeng Li, Maria C. Muñiz, Kelley M. Kidwell, Kimberly Aung, Dafydd G. Thomas, Martha E. Brown, Vandana G. Abramson, William J. Irvin, Nan Lin, Mine...> ;Clinical Cancer Research. 2015 Jun 15
5 citations
Patients' Understanding of How Genotype Variation Affects Benefits of Tamoxifen Therapy for Breast Cancer
Noel T. Brewer, Jessica T. DeFrank, Wing Keung Chiu, Joseph G. Ibrahim, Christine M. Walko, Peter Rubin, Oludamilola Olajide, Susan G. Moore, Rachael E. Raab, Daniel R...> ;Public Health Genomics. 2014 Jan 1
61 citations
Tamoxifen and CYP2D6: A Contradiction of Data
Daniel L. Hertz, Howard L. McLeod, William J. Irvin> ;The Oncologist. 2012 May 1
8 citations
Assessing the utility of whole genome amplified DNA as a template for DMET Plus array.
Yi Jing He, Anne Misher, William J. Irvin, Alison A. Motsinger-Reif, Howard L. McLeod, Janelle M. Hoskins> ;Clinical Chemistry and Laboratory Medicine. 2012 Feb 14
7 citations
A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors
Hanna K. Sanoff, Janine M. Davies, Christine M. Walko, William J. Irvin, Larry W. Buie, Kimberly Keller, Anastasia Ivanova, Wing Keung Chiu, Bert H. O'Neil, Thomas E. ...> ;Investigational New Drugs. 2011 Oct 1
61 citations
Symptom Management in Metastatic Breast Cancer
William J. Irvin, Hyman B. Muss, Deborah K. Mayer> ;The Oncologist. 2011 Sep 1
131 citations
Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
William J. Irvin, Christine M. Walko, Karen E. Weck, Joseph G. Ibrahim, Wing Keung Chiu, E. Claire Dees, Susan G. Moore, Oludamilola Olajide, Mark L. Graham, Sean Thom...> ;Journal of Clinical Oncology. 2011 Aug 20
Comprehensive CYP2D6 genotyping in a multiracial population shows differences in allele frequencies between races.
Irvin WJ, Weck KE, Walko CM, Chiu WK, Rubin P, Olajide OA, Moore SG, Raab RE, Carrizosa DR, Corso SW, Schwartz G, Anderson SM, Friedman KJ, Dees EC, Flockhart D, Peppe...> ;J. Clin. Oncol.. 2011-05-20
TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigat...
Forero-Torres A, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Mayer IA, Storniolo AM, Traina TA, Hayes DF, Rimawi MF, Goetz MP, Esteva FJ, Irvin WJ, Wolff AC> ;J. Clin. Oncol.. 2011-05-20
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.
Brewer NT, Walko CM, Chiu WK, Dressler LG, Yuen A, Rubin P, Olajide OA, Moore SG, Raab RE, Carrizosa DR, Corso SW, Schwartz G, Peppercorn JM, McLeod HL, Carey LA, Irvi...> ;J. Clin. Oncol.. 2011-05-20
P16INK4aexpression after chemotherapy in older women with early-stage breast cancer.
Muss HB, Krishnamurthy J, Alston SM, Lacy AC, Jolly TA, Williams G, Carey LA, Dees EC, Anders CK, Irvin WJ, Sharpless NE> ;J. Clin. Oncol.. 2011-05-20
22 citations
Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.
William J. Irvin, Robert Z. Orlowski, Wing Keung Chiu, Lisa A. Carey, Frances A. Collichio, Philip S. Bernard, Inge J. Stijleman, Charles M. Perou, Anastasia Ivanova, ...> ;Clinical Breast Cancer. 2010 Dec 1
2 citations
Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care.
Tejinder Rakhra-Burris, J. Todd Auman, Patricia A. Deverka, Lynn G. Dressler, James P. Evans, Richard M. Goldberg, Tammy M. Havener, Janelle M. Hoskins, Daniel E Jonas...> ;Pharmacogenomics. 2010 Jan 1
Comprehensive CYP2D6 genotyping in a multiracial U.S. breast cancer population.
Irvin WJ, Carey LA, Olajide O, Dees EC, Peppercorn J, Chiu WK, Walko CM, McLeod HL, Evans JP, Weck KE> ;J. Clin. Oncol.. 2009-05-20
212 citations
What is triple-negative breast cancer?
William J. Irvin, Lisa A. Carey> ;European Journal of Cancer. 2008 Dec 1
Join now to see all

Press Mentions

Bon Secours Offering New Therapy to Help Reduce Hair Loss Caused by ChemoOctober 2nd, 2019
How the Sisters Network Plans to Save Women’s Lives This YearSeptember 27th, 2019
Medical Options for the Treatment of Breast Cancer on Coast LiveOctober 26th, 2018

Hospital Affiliations

Bon Secours St. Francis Medical CenterMidlothian, Virginia
Bon Secours Richmond Community HospitalRichmond, Virginia